Investor's Business Daily - Investing RSS http://ift.tt/1rEj6dR Alexion Pharmaceuticals (ALXN) may be a one-hit wonder, but it's a very lucrative one. Despite a small market for its only marketed drug, Soliris, Alexion generated $1.55 billion in sales in 2013, up 37% from 2012. This year, sales are seen rising 42% to $2.2 billion. Soliris is considered an orphan drug because it's used to treat rare medical conditions that don't get a lot attention from other drugmakers. Soliris is used to treat a blood
No comments:
Post a Comment